Eliquis (apixaban) is a prescription anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It is one of the most widely prescribed anticoagulants, and is considered to be an effective and safe treatment option for many patients. However, there are potential risks associated with Eliquis, particularly in the elderly population. This article will discuss the potential risks of Eliquis in the elderly, including side effects, potential interactions with other medications, and the importance of monitoring for adverse reactions.
Eliquis is a direct factor Xa inhibitor, which works by blocking the action of factor Xa, a protein involved in the clotting process. This helps to prevent the formation of blood clots, which can cause serious health problems such as stroke, heart attack, and pulmonary embolism. Eliquis is generally well-tolerated, but it is important to be aware of the potential risks associated with taking this medication.
The elderly population is particularly vulnerable to the side effects of Eliquis. Common side effects of Eliquis include nausea, headache, dizziness, and fatigue. Elderly patients may also be more likely to experience bleeding, including bleeding from the nose, gums, or rectum, as well as bruising more easily. In some cases, Eliquis can also cause anemia, which can lead to fatigue and shortness of breath.
Eliquis can interact with other medications, including non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and other anticoagulants. It is important to discuss all medications that a patient is taking with their doctor, as some medications may increase the risk of bleeding or other side effects when taken with Eliquis.
It is important for elderly patients taking Eliquis to be monitored closely for any adverse reactions, such as bleeding or bruising. Patients should also be aware of the signs and symptoms of anemia, such as fatigue and shortness of breath. Regular blood tests should be done to monitor for any changes in the blood.
Eliquis is a widely prescribed anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. While Eliquis is generally well-tolerated, there are potential risks associated with taking this medication, particularly in the elderly population. It is important to be aware of the potential side effects of Eliquis, as well as any potential interactions with other medications. Regular monitoring for adverse reactions is also important, as this can help to detect any problems early and reduce the risk of serious complications.
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation